Back to top

Barclays Sticks to Their Sell Rating for Hikma Pharmaceuticals (HIK)

In a report released today, James Gordon CFA from Barclays maintained a Sell rating on Hikma Pharmaceuticals, with a price target of £13.50. Gordon...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Hikma Pharmaceuticals Plc (HKMPF)